Medicinalproductindication-example.xml

Example of medicinalproductindication (id = "example")

<?xml version="1.0" encoding="UTF-8"?>

<MedicinalProductIndication xmlns="http://hl7.org/fhir">
  <id value="example"/> 
    <text> <status value="generated"/> <div xmlns="http://www.w3.org/1999/xhtml"><p> <b> Generated Narrative with Details</b> </p> <p> <b> id</b> : example</p> <p> <b> diseaseSymptomProcedure</b> : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone
         elective hip\nor knee replacement surgery.\nPrevention of stroke and systemic embolism
         in adult patients with non-valvular atrial fibrillation\n(NVAF), with one or more risk
         factors, such as prior stroke or transient ischaemic attack (TIA); age\n≥ 75 years; hypertension;
         diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\nTreatment of deep vein
         thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\nDVT and PE
         in adults (see section 4.4 for haemodynamically unstable PE patients). <span> (Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboem
          bolismprophylaxis' = 'Venousthromboembolismprophylaxis)</span> </p> <p> <b> comorbidity</b> : Hipsurgery <span> (Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)</span> </p> <p> <b> intendedEffect</b> : PRYLX <span> (Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)</span> </p> <p> <b> population</b> : </p> </div> </text> <diseaseSymptomProcedure> 
      <coding> 
        <system value="http://ema.europa.eu/example/indicationasdisease-symptom-procedure"/> 
        <code value="Venousthromboembolismprophylaxis"/> 
      </coding> 
      <text value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone
     elective hip\nor knee replacement surgery.\nPrevention of stroke and systemic embolism
     in adult patients with non-valvular atrial fibrillation\n(NVAF), with one or more risk
     factors, such as prior stroke or transient ischaemic attack (TIA); age\n≥ 75 years; hypertension;
     diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\nTreatment of deep vein
     thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\nDVT and PE
     in adults (see section 4.4 for haemodynamically unstable PE patients)."/> 
    </diseaseSymptomProcedure> 
    <comorbidity> 
      <coding> 
        <system value="http://ema.europa.eu/example/comorbidity"/> 
        <code value="Hipsurgery"/> 
      </coding> 
    </comorbidity> 
    <intendedEffect> 
      <coding> 
        <system value="http://ema.europa.eu/example/intendedeffect"/> 
        <code value="PRYLX"/> 
      </coding> 
    </intendedEffect> 
    <population> 
      <ageRange> 
        <low> 
          <value value="18"/> 
          <unit value="a"/> 
        </low> 
      </ageRange> 
    </population> 
</MedicinalProductIndication>